NCT05745142View on ClinicalTrials.gov

A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.

CompletedOBSERVATIONAL
Enrollment

376

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

February 23, 2023

Study Completion Date

February 23, 2023

Conditions
Carcinoma, Renal CellClear-cell Metastatic Renal Cell Carcinoma
Interventions
DRUG

Sunitinib

as provided in real world practice

Trial Locations (1)

34394

Pfizer, Istanbul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05745142 - A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine. | Biotech Hunter | Biotech Hunter